Company / Current Assets
Acadia Pharmaceuticals Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$1.1B
FY2025
5-year range
$507.9M / $1.1B
FY2021-FY2025
Trend
+13.2%
vs FY2024
Sector context
#44 of 213
Health Care
What the data says
Acadia Pharmaceuticals's current assets of $1.1B is higher than 79% of companies in the Health Care sector (FY2025). Current Assets has increased for 3 consecutive years, from $508M in FY2022 to $1.1B in FY2025.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +8.2%. Top quartile in the Health Care sector.
Improved from $616M to $1.1B over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +27.9%
- 5-Year CAGR
- +8.2%
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 213This company $1.1B Sector average $2.5B
▼
-57.9% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's current assets has grown for 3 consecutive years.
- 5-year CAGR of +8.2%, indicating consistent growth.
- In FY2025, current assets increased 13.2% year-over-year.
- Ranks #44 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +13.2% |
| FY2024 | $938.3M | +52.3% |
| FY2023 | $616.1M | +21.3% |
| FY2022 | $507.9M | -17.8% |
| FY2021 | $617.8M | -13.9% |
| FY2020 | $717.6M | -5.6% |
| FY2019 | $760.3M | +44.5% |
| FY2018 | $526.1M | +40.9% |
| FY2017 | $373.5M | -31.8% |
| FY2016 | $547.9M | +150.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026